
Raquibul Hannan, M.D., Ph.D.
Titles and Appointments
Chief of Genitourinary Radiation Oncology Service
Professor
- School
- Medical School
- Department
- Radiation Oncology | Immunology | Urology
- Graduate Programs
- Cancer Biology
You have reached the Academic Profile.
For more information on the doctor and patient care, please visit the clinical profile.
Raquibul Hannan, M.D., Ph.D., is a Professor of Radiation Oncology and Chief of Genitourinary Radiation Oncology Service at UT Southwestern Medical Center.
Dr. Hannan earned his medical degree from State University of New York (SUNY) at Brooklyn’s Downstate College of Medicine and his Ph.D. from the SUNY Downstate School of Graduate Studies. He completed his radiation oncology residency training at Albert Einstein College of Medicine and Montefiore Medical Center.
Dr. Hannan leads the Hannan Lab at UT Southwestern, which aims to understand and exploit the immunogenic properties of tumor irradiation in integrating it with immunotherapy to improve cancer patient outcomes. His lab is currently involved in performing translational studies on a number of stereotactic ablative radiotherapy (SAbR) and i-SAbR (immunotherapy + SAbR) clinical trials.
Dr. Hannan has led and completed multiple investigator-initiated clinical trials investigating the application of SAbR for prostate and kidney cancer. He is the national Chair/PI of a phase three randomized trial SOAR (EA-8211) that is investigating SAbR in oligometastatic renal cell carcinoma patients. In the clinic, he is investigating the application of adaptive SAbR or PULSAR (Personalized Ultra-fractionated Stereotactic Ablative Radiation) for the treatment of locally advanced and metastatic kidney cancer.
As a leading researcher on immunologic effects of radiation and immunotherapy, Dr. Hannan holds two international patents and has presented his findings at numerous symposiums and conferences across the world. He is a member of several professional societies, including the American Society of Radiation Oncology (ASTRO), the American Board of Radiology (ABR), and the American Society of Clinical Oncology (ASCO).